Khasianine
Based on 3 publication(s) in Google Scholar
Khasianine is a steroidal glycoalkaloid. Khasianine alleviates psoriasis-like skin inflammation by inhibiting the TNF-α/NF-κB axis. Khasianine can downregulate the RhoA pathway and exhibits potential antimetastatic activity. Khasianine upregulates the expression of TNFR I and TNFR II without inducing apoptotic effects. Khasianine can be used in studies related to psoriasis, pancreatic ductal adenocarcinoma, and liver cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.11%
- CAS No.: 32449-98-2
- 화학식: C39H63NO11
- 분자량:721.92
-
보관:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Glycoside Compound Library
HY-L042
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Alkaloids Library
HY-L071
-
Anti-Cancer Natural Product Library
HY-L107
-
Plant-Sourced Natural Product Library
HY-L115
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Natural Product Diversity Scaffold Library
HY-L245
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Khasianine
More
Biological Activity
IC50: antitumor activity[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| PLC-PRF-5 | ED50 |
8.6 μg/mL
Compound: khasianine
|
Cytotoxicity against human PLC/PRF/5 cells by microassay
Cytotoxicity against human PLC/PRF/5 cells by microassay
|
[PMID: 2380724] |
Khasianine (3.2-50 nM; 24 h) dose-dependently inhibits TNF-α-induced phosphorylation of NF-κB p65 at the Ser536 site in HaCaT cells without altering the level of total NF-κB p65[1].
Khasianine (3.2-50 nM; 24 h) dose-dependently inhibits TNF-α-induced IL-17A and IL-33 protein expression in HaCaT cells[1].
Khasianine (50 nM) blocks TNF-α-induced nuclear translocation of NF-κB p65 in HaCaT cells[1].
Khasianine (50 nM) displaces NF-κB p65 from the promoter regions of IL-17A and IL-33, thereby inhibiting TNF-α-induced transactivation of these cytokines in HaCaT cells[1].
Khasianine (3.2-12.5 nM) inhibits TNF-α-induced IL-17A mRNA expression in HaCaT cells in a dose-dependent manner, and significantly reduces TNF-α-induced IL-33 mRNA expression in these cells at a concentration of 12.5 nM[1].
Khasianine (50-200 μM; 6 days) shows no obvious cytotoxicity against HaCaT cells at concentrations up to 200 μM during the 6-day incubation period[1].
Khasianine (30-60 μg/mL) does not induce apoptotic cell death (characterized by a sub-G1 peak) in human hepatocellular carcinoma Hep3B cells even at concentrations as high as 60 μg/mL[3].
Khasianine (30-100 μg/mL; 48 h) inhibits the proliferation of human Suit2-007 cells and rat ASML pancreatic cancer cells, with IC50 values of 50 μg/mL and 54 μg/mL, respectively[2].
Khasianine (up to 20 μg/mL; 16 h) exhibits extremely low cytotoxicity against human hepatocellular carcinoma Hep3B cells, with an IC50 greater than 20 μg/mL[3].
Khasianine (50 μg/mL; 48 h) regulates the mRNA expression of glucose-sensitive LSBP in human Suit2-007 pancreatic cancer cells, with the most significant downregulation observed in lactose-sensitive LSBP, and downregulates the Sirtuin, RhoGTPase and RhoA signaling pathways[2].
Khasianine (50 μg/mL; 48 h) regulates the protein expression of glucose-sensitive LSBP in human Suit2-007 pancreatic cancer cells, with the most significant down-regulation observed in lactose-sensitive LSBP[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HaCaT
-
Concentration:3.2, 12.5, 50 nM
-
Incubation Time:24 h
-
Result:Inhibited TNF-α-induced phosphorylation of NF-κB p65 at ser536 in a dose-dependent manner.
Had no effect on total NF-κB p65 expression.\nDownregulated TNF-α-induced IL-17A and IL-33 protein expression in a dose-dependent manner.
-
Cell Line:HaCaT
-
Concentration:50, 100, 200 μM
-
Incubation Time:up to 6 days
-
Result:Showed no obvious cytotoxicity in HaCaT cells treated at concentrations up to 200 μM over the 6-day incubation period.
Maintained cell viability comparable to DMSO-treated controls.
-
Cell Line:human pancreatic ductal adenocarcinoma (PDAC) Suit2-007 cells, rat PDAC ASML cells
-
Concentration:30, 40, 50, 60, 80, 100 μg/mL
-
Incubation Time:48 h
-
Result:Inhibited proliferation of Suit2-007 cells with an IC50 value of 50 μg/mL.
Inhibited proliferation of ASML cells with an IC50 value of 54 μg/mL.
-
Cell Line:human hepatoma Hep3B cells
-
Concentration:20 μg/mL
-
Incubation Time:30 min
-
Result:Up-regulated TNFR I gene expression to the highest extent among the tested alkaloids, resulting in a TNFR II/I expression ratio of 0.95 (compared to a control ratio of 1.37).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (8 to 10 weeks of age; n=5 per treatment group; imiquimod-induced psoriasis-like skin inflammation)[1]
-
Dosage:0.1 μg/g, 1 μg/g, 5 μg/g, 25 μg/g; 5 μg/g (most effective)
-
Administration:topical; 3 times daily; 4 days
-
Result:Reduced clinical features of psoriasis-like inflammation, including scales, epidermal thickness, and immune cell infiltration.
Significantly reduced CD4+ T helper cells and macrophages in skin lesions.
Markedly decreased TNF-α-positive cells, total NF-κB p65-positive cells, phosphorylated NF-κB p65 (ser536)-positive cells, IL-17A-positive cells, and IL-33-positive cells in both epidermis and dermis.
Chemical Information
-
CAS No. 32449-98-2
-
Appearance Solid
-
분자량 721.92
-
화학식 C39H63NO11
-
Color White to off-white
-
SMILES
C[C@@H]1[C@@]2(CC[C@@H](C)CN2)O[C@](C[C@@]3([H])[C@@](CC=C4[C@@]5(CC[C@H](O[C@]([C@@H]([C@@H](O)[C@@H]6O[C@@](O[C@@H](C)[C@H](O)[C@H]7O)([H])[C@@H]7O)O)([H])O[C@@H]6CO)C4)C)([H])[C@]5([H])CC8)([H])[C@@]1([H])[C@]38C
-
Structure Classification
-
Initial Source
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Total alkaloids of Fritillaria unibracteata var. wabuensis bulbus ameliorate chronic asthma via the TRPV1/Ca2+/NFAT pathway. [Abstract]2023 Sep:118:154946. PMID: 37421766 -
J Ethnopharmacol
Khasianine ameliorates psoriasis-like skin inflammation and represses TNF-α/NF-κB axis mediated transactivation of IL-17A and IL-33 in keratinocytes. [Abstract]2022 Jun 28:292:115124. PMID: 35183690 -
Molecules
Metabolite Profiling and Anti-Inflammatory Activities of Fritillaria cirrhosa D. Don Bulbs Derived from Tissue Culture. [Abstract]2025 Jan 31;30(3):623. PMID: 39942727
용액&용해도
DMSO : 50 mg/mL (69.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.46 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.46 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (286 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yang Y, et al. Khasianine ameliorates psoriasis-like skin inflammation and represses TNF-α/NF-κB axis mediated transactivation of IL-17A and IL-33 in keratinocytes. Journal of ethnopharmacology. 2022 Jun 28;292:115124. [Content Brief]
[2]. Sagini MN, et al. Khasianine Affects the Expression of Sugar-Sensitive Proteins in Pancreatic Cancer Cells, Which Are Altered in Data from the Rat Model and Patients. ACS pharmacology & translational science. 2023 May 12;6(5):727-737. [Content Brief]
[3]. Chang LC, et al. The rhamnose moiety of solamargine plays a crucial role in triggering cell death by apoptosis. Biochemical and biophysical research communications. 1998 Jan 06;242(1):21-5. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.3852 mL | 6.9260 mL | 13.8520 mL | 34.6299 mL |
| 5 mM | 0.2770 mL | 1.3852 mL | 2.7704 mL | 6.9260 mL | |
| 10 mM | 0.1385 mL | 0.6926 mL | 1.3852 mL | 3.4630 mL | |
| 15 mM | 0.0923 mL | 0.4617 mL | 0.9235 mL | 2.3087 mL | |
| 20 mM | 0.0693 mL | 0.3463 mL | 0.6926 mL | 1.7315 mL | |
| 25 mM | 0.0554 mL | 0.2770 mL | 0.5541 mL | 1.3852 mL | |
| 30 mM | 0.0462 mL | 0.2309 mL | 0.4617 mL | 1.1543 mL | |
| 40 mM | 0.0346 mL | 0.1731 mL | 0.3463 mL | 0.8657 mL | |
| 50 mM | 0.0277 mL | 0.1385 mL | 0.2770 mL | 0.6926 mL | |
| 60 mM | 0.0231 mL | 0.1154 mL | 0.2309 mL | 0.5772 mL |
Khasianine Related Classifications
HY-N2322 Related Classifications
Powered by Bioz